Derisking Drug Development with a Disease-Focused Approach to Gain Investor Confidence for the Evolving Muscular Disorder Landscape
9:30 am - Wednesday 27th January 2027
- How Solve FSHD are positioned as strategic investors to provide early funding, scientific guidance, and credibility that advance pipelines for disease-focused progress
- Building and validating key drug development tools, including prognostic biomarkers, molecular biomarkers, and clinically meaningful outcome measures, to reduce uncertainty and strengthen development pathways
- Demonstrating how foundation-led partnerships can bridge critical funding and knowledge gaps, creating a stronger path from discovery through clinical development for muscular disorder therapies
